FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,030,361 | -50.1% | 1,429,416 | +12.0% | 0.00% | -100.0% |
| Q2 2023 | $6,077,720 | -15.5% | 1,276,832 | +1.2% | 0.00% | 0.0% |
| Q1 2023 | $7,194,398 | -59.0% | 1,262,175 | -27.4% | 0.00% | -50.0% |
| Q4 2022 | $17,537,178 | -42.9% | 1,738,075 | +26.9% | 0.00% | -50.0% |
| Q3 2022 | $30,697,000 | -23.7% | 1,369,721 | -15.7% | 0.00% | -20.0% |
| Q2 2022 | $40,250,000 | -15.7% | 1,624,269 | +31.9% | 0.01% | -16.7% |
| Q1 2022 | $47,757,000 | -50.0% | 1,231,802 | -24.5% | 0.01% | -50.0% |
| Q4 2021 | $95,435,000 | +51.9% | 1,631,076 | +53.8% | 0.01% | +50.0% |
| Q3 2021 | $62,840,000 | -23.8% | 1,060,241 | +11.6% | 0.01% | -27.3% |
| Q2 2021 | $82,429,000 | -17.2% | 949,773 | -21.3% | 0.01% | -26.7% |
| Q1 2021 | $99,559,000 | +12.6% | 1,207,497 | +24.2% | 0.02% | +7.1% |
| Q4 2020 | $88,438,000 | +683.7% | 972,594 | +244.5% | 0.01% | +600.0% |
| Q3 2020 | $11,284,000 | +61.9% | 282,308 | +39.0% | 0.00% | 0.0% |
| Q2 2020 | $6,968,000 | +21.0% | 203,097 | -21.7% | 0.00% | 0.0% |
| Q1 2020 | $5,760,000 | -50.2% | 259,331 | -56.2% | 0.00% | -33.3% |
| Q4 2019 | $11,574,000 | +259.2% | 591,458 | +185.1% | 0.00% | +200.0% |
| Q3 2019 | $3,222,000 | -41.3% | 207,466 | -23.3% | 0.00% | 0.0% |
| Q2 2019 | $5,489,000 | +157.5% | 270,423 | +122.9% | 0.00% | 0.0% |
| Q1 2019 | $2,132,000 | -54.9% | 121,343 | -67.1% | 0.00% | 0.0% |
| Q4 2018 | $4,728,000 | +37.6% | 368,466 | +74.7% | 0.00% | 0.0% |
| Q3 2018 | $3,435,000 | -17.4% | 210,923 | -42.5% | 0.00% | 0.0% |
| Q2 2018 | $4,161,000 | +88.1% | 366,944 | +61.9% | 0.00% | 0.0% |
| Q1 2018 | $2,212,000 | -30.3% | 226,651 | -56.3% | 0.00% | 0.0% |
| Q4 2017 | $3,172,000 | +37.8% | 519,062 | -10.7% | 0.00% | 0.0% |
| Q3 2017 | $2,302,000 | +12.1% | 581,237 | -8.3% | 0.00% | 0.0% |
| Q2 2017 | $2,054,000 | -63.1% | 633,944 | -48.2% | 0.00% | 0.0% |
| Q1 2017 | $5,566,000 | +99.1% | 1,223,292 | +9.8% | 0.00% | – |
| Q4 2016 | $2,796,000 | +279500.0% | 1,114,062 | +659108.3% | 0.00% | – |
| Q3 2016 | $1,000 | -50.0% | 169 | -83.6% | 0.00% | – |
| Q2 2016 | $2,000 | -94.4% | 1,030 | -94.9% | 0.00% | – |
| Q1 2016 | $36,000 | +111.8% | 20,002 | +300.0% | 0.00% | – |
| Q4 2015 | $17,000 | -67.3% | 5,000 | -48.1% | 0.00% | – |
| Q3 2015 | $52,000 | 0.0% | 9,626 | +19.5% | 0.00% | – |
| Q2 2015 | $52,000 | +160.0% | 8,057 | +99.7% | 0.00% | – |
| Q4 2014 | $20,000 | -57.4% | 4,035 | -56.3% | 0.00% | – |
| Q3 2014 | $47,000 | +1466.7% | 9,235 | +2546.1% | 0.00% | – |
| Q1 2014 | $3,000 | – | 349 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |